HOUSTON, May 19, 2026 /PRNewswire/ -- Delphi Diagnostics today announced the appointment of Eric Lindquist as Chief Financial Officer, effective April 1, 2026. Mr. Lindquist brings decades of ...
Peer-reviewed manuscript demonstrates the Endocrine Activity IndexTM Recurrence Risk (EAIRR) enhances risk stratification beyond Recurrence Score® and is predictive of endocrine therapy benefit ...
HOUSTON, June 22, 2026 /PRNewswire/ -- Delphi Diagnostics today announced the publication of findings from the GEICAM/9906 clinical trial demonstrating that the company's Endocrine Activity Index (EAI ...
This analysis independently validated previous findings and further helps to establish EAI as the first genomic assay shown to predict benefit from a contemporary taxane-based chemotherapy regimen in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results